The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
PLK1, A Potential Target for Cancer Therapy
Open accessAbstract
Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of PLK1 may promote cancerous transformation and drive its progression. PLK1 overexpression has been found in a variety of human cancers and was associated with poor prognoses in cancers. Many studies have showed that inhibition of PLK1 could lead to death of cancer cells by interfering with multiple stages of mitosis. Thus, PLK1 is expected to be a potential target for cancer therapy. In this article, we examined PLK1's structural characteristics, its regulatory roles in cell mitosis, PLK1 expression, and its association with survival prognoses of cancer patients in a wide variety of cancer types, PLK1 interaction networks, and PLK1 inhibitors under investigation. Finally, we discussed the key issues in the development of PLK1-targeted cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
BioGRID: a general repository for interaction datasets
Stark, C. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj109 · Cited by 3,960
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery
Macůrek, L., Lindqvist, A., Lim, D., Lampson, M. A., Klompmaker, R., Freire, R., Clouin, C., Taylor, S. S., Yaffe, M. B., & Medema, R. H. (2008) · Nature · doi:10.1038/nature07185 · Cited by 710
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics
Gutteridge, R. E. A., Ndiaye, M. A., Liu, X., & Ahmad, N. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0897 · Cited by 406
Rudolph, D., Steegmaier, M., Hoffmann, M., Grauert, M., Baum, A., Quant, J., Haslinger, C., Garin-Chesa, P., & Adolf, G. R. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2445 · Cited by 398
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent
Gumireddy, K., Reddy, M. V. R., Cosenza, S. C., Nathan, R. B., Baker, S. J., Papathi, N., Jiang, J., Holland, J., & Reddy, E. P. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.009 · Cited by 367
Fu, Z., Malureanu, L., Huang, J., Wang, W., Li, H., van Deursen, J. M., Tindall, D. J., & Chen, J. (2008) · Nature Cell Biology · doi:10.1038/ncb1767 · Cited by 355
Activation of cyclin B1–Cdk1 synchronizes events in the nucleus and the cytoplasm at mitosis
Gavet, O., & Pines, J. (2010) · Journal of Cell Biology · doi:10.1083/jcb.200909144 · Cited by 334
Spankuch-Schmitt, B., Bereiter-Hahn, J., Kaufmann, M., & Strebhardt, K. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.24.1863 · Cited by 327
Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer
Wolf, G., Elez, R., Doermer, A., Holtrich, U., Ackermann, H., Stutte, H. J., Altmannsberger, H.-M., Rübsamen-Waigmann, H., & Strebhardt, K. (1997) · Oncogene · doi:10.1038/sj.onc.1200862 · Cited by 323
Elowe, S., Hümmer, S., Uldschmid, A., Li, X., & Nigg, E. A. (2007) · Genes & Development · doi:10.1101/gad.436007 · Cited by 312
Polo-Like Kinases: A Team in Control of the Division
Weerdt, B. C. M. V. D., & Medema, R. H. (2006) · Cell Cycle · doi:10.4161/cc.5.8.2692 · Cited by 300
Structure and function of Polo-like kinases
Lowery, D. M., Lim, D., & Yaffe, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208280 · Cited by 293
Holtrich, U., Wolf, G., Bräuninger, A., Karn, T., Böhme, B., Rübsamen-Waigmann, H., & Strebhardt, K. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1736 · Cited by 275
From Plk1 to Plk5: Functional evolution of polo-like kinases
de Cárcer, G., Manning, G., & Malumbres, M. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16494 · Cited by 273
Polo‐like kinase 1 (PLK1) is overexpressed in primary colorectal cancers
Takahashi, T., Sano, B., Nagata, T., Kato, H., Sugiyama, Y., Kunieda, K., Kimura, M., Okano, Y., & Saji, S. (2003) · Cancer Science · doi:10.1111/j.1349-7006.2003.tb01411.x · Cited by 265
Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation
Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., & Nakagawara, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314182200 · Cited by 264
Targeting Polo-like Kinase in Cancer Therapy
Degenhardt, Y., & Lampkin, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1380 · Cited by 262
Cheng, K.-Y. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg558 · Cited by 254
WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
De Witt Hamer, P. C., Mir, S. E., Noske, D., Van Noorden, C. J. F., & Würdinger, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2537 · Cited by 249
Inhibition of Polo-like Kinase 1 by Blocking Polo-Box Domain-Dependent Protein-Protein Interactions
Reindl, W., Yuan, J., Krämer, A., Strebhardt, K., & Berg, T. (2008) · Chemistry & Biology · doi:10.1016/j.chembiol.2008.03.013 · Cited by 232
Knecht, R., Elez, R., Oechler, M., Solbach, C., von Ilberg, C., & Strebhardt, K. (1999) · PubMed · Cited by 232
Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology
Schöffski, P. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0010 · Cited by 229
Mundt, K. E., Golsteyn, R. M., Lane, H. A., & Nigg, E. A. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.7378 · Cited by 200
Santamaria, A., Neef, R., Eberspächer, U., Eis, K., Husemann, M., Mumberg, D., Prechtl, S., Schulze, V., Siemeister, G., Wortmann, L., et al. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-05-0517 · Cited by 199
Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades
Weichert, W., Schmidt, M., Gekeler, V., Denkert, C., Stephan, C., Jung, K., Loening, S., Dietel, M., & Kristiansen, G. (2004) · The Prostate · doi:10.1002/pros.20050 · Cited by 188
Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma
Weichert, W., Denkert, C., Schmidt, M., Gekeler, V, Wolf, G., Köbel, M., Dietel, M., & Hauptmann, S. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601610 · Cited by 177
Polo-like kinase 1 reaches beyond mitosis—cytokinesis, DNA damage response, and development
Takaki, T., Trenz, K., Costanzo, V., & Petronczki, M. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2008.10.005 · Cited by 176
Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease
Kneisel, L., Strebhardt, K., Bernd, A., Wolter, M., Binder, A., & Kaufmann, R. (2002) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2002.290605.x · Cited by 158
Qi, W., Tang, Z., & Yu, H. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e06-03-0240 · Cited by 157
Polo-like Kinase 1 and Chk2 Interact and Co-localize to Centrosomes and the Midbody
Tsvetkov, L. M., Xu, X., Li, J., & Stern, D. F. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211202200 · Cited by 156
Rosner, M., Hanneder, M., Siegel, N., Valli, A., & Hengstschläger, M. (2008) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2008.01.001 · Cited by 145
Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications
Weichert, W., Kristiansen, G., Winzer, K., Schmidt, M., Gekeler, V., Noske, A., Müller, B., Niesporek, S., Dietel, M., & Denkert, C. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1212-8 · Cited by 141
In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1
Lansing, T. J., McConnell, R. T., Duckett, D. R., Spehar, G. M., Knick, V. B., Hassler, D. F., Noro, N., Furuta, M., Emmitte, K. A., Gilmer, T. M., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0543 · Cited by 140
Reagan‐Shaw, S., & Ahmad, N. (2005) · The FASEB Journal · doi:10.1096/fj.04-2910fje · Cited by 138
Yang, L., Zhou, Y., Li, Y., Zhou, J., Wu, Y., Cui, Y., Yang, G. S., & Hong, Y. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.12.003 · Cited by 137
The tumor suppressor CYLD regulates entry into mitosis
Stegmeier, F. P., Sowa, M. E., Nalepa, G., Gygi, S. P., Harper, J. W., & Elledge, S. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703268104 · Cited by 137
The Role of Polo-like Kinase 1 in Carcinogenesis: Cause or Consequence?
Cholewa, B. D., Liu, X., & Ahmad, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-2197 · Cited by 135
Prognostic significance of polo-like kinase expression in esophageal carcinoma.
Tokumitsu, Y., Mori, M., Tanaka, S., Akazawa, K., Nakano, S., & Niho, Y. (1999) · International Journal of Oncology · doi:10.3892/ijo.15.4.687 · Cited by 134
p53-dependent repression of polo-like kinase-1 (PLK1)
McKenzie, L., King, S., Marcar, L., Nicol, S., Dias, S. S., Schumm, K., Robertson, P., Bourdon, J., Perkins, N. D., Fuller-Pace, F. V., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.20.13532 · Cited by 120
Molecular dynamics of PLK1 during mitosis
Schmucker, S., & Sumara, I. (2014) · Molecular & Cellular Oncology · doi:10.1080/23723548.2014.954507 · Cited by 118
The Bub1–Plk1 kinase complex promotes spindle checkpoint signalling through Cdc20 phosphorylation
Jia, L., Li, B., & Yu, H. (2016) · Nature Communications · doi:10.1038/ncomms10818 · Cited by 117
Wolf, G., Hildenbrand, R., Schwar, C., Grobholz, R., Kaufmann, M., Stutte, H.-J., Strebhardt, K., & Bleyl, U. (2000) · Pathology - Research and Practice · doi:10.1016/s0344-0338(00)80107-7 · Cited by 111
Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., & Miyakawa, I. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00703-5 · Cited by 111
Spotlight on Volasertib: Preclinical and Clinical Evaluation of a Promising Plk1 Inhibitor
den Bossche, J. V., Lardon, F., Deschoolmeester, V., Pauw, I. D., Vermorken, J. B., Specenier, P. M., Pauwels, P., Peeters, M., & Wouters, A. (2016) · Medicinal Research Reviews · doi:10.1002/med.21392 · Cited by 109
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance
McInnes, C., Mazumdar, A., Mezna, M., Meades, C. K., Midgley, C., Scaërou, F., Carpenter, L., Mackenzie, M., Taylor, P., Walkinshaw, M. D., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio825 · Cited by 99
Cross-Talk between AURKA and Plk1 in Mitotic Entry and Spindle Assembly
Asteriti, I. A., Mattia, F. D., & Guarguaglini, G. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00283 · Cited by 99
Yuan, J., Sanhaji, M., Krämer, A., Reindl, W., Hofmann, M., Kreis, N., Zimmer, B., Berg, T., & Strebhardt, K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.06.031 · Cited by 98
Benoit, D. S. W., Henry, S. M., Shubin, A. D., Hoffman, A. S., & Stayton, P. S. (2010) · Molecular Pharmaceutics · doi:10.1021/mp9002255 · Cited by 97
Mahajan, U. M., Teller, S., Sendler, M., Palankar, R., van den Brandt, C., Schwaiger, T., Kühn, J., Ribback, S., Glöckl, G., Evert, M., et al. (2016) · Gut · doi:10.1136/gutjnl-2016-311393 · Cited by 97
Kopnin, B. P. (2000) · PubMed · Cited by 96
Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
Hu, X., & Zhang, Z. (2015) · Trends in Genetics · doi:10.1016/j.tig.2015.11.003 · Cited by 94
Identification of potential synthetic lethal genes to p53 using a computational biology approach
Wang, X., & Simon, R. (2013) · BMC Medical Genomics · doi:10.1186/1755-8794-6-30 · Cited by 93
Self-citationLee, M.-Y., Daniels, M. J., & Venkitaraman, A. R. (2003) · Oncogene · doi:10.1038/sj.onc.1207223 · Cited by 93
King, S., Purdie, C. A., Bray, S. E., Quinlan, P., Jordan, L. B., Thompson, A. M., & Meek, D. W. (2012) · Breast Cancer Research · doi:10.1186/bcr3136 · Cited by 90
Molecular interactions of Polo-like-kinase 1 with the mitotic kinesin-like protein CHO1/MKLP-1
Liu, X., Zhou, T., Kuriyama, R., & Erikson, R. L. (2004) · Journal of Cell Science · doi:10.1242/jcs.01173 · Cited by 89
Hu, K., Law, J. H., Fotovati, A., & Dunn, S. E. (2012) · Breast Cancer Research · doi:10.1186/bcr3107 · Cited by 89
Gleixner, K. V., Ferenc, V., Peter, B., Gruze, A., Meyer, R. A., Hadzijusufovic, E., Cerny‐Reiterer, S., Mayerhofer, M., Pickl, W. F., Sillaber, C., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2181 · Cited by 87
Astrinidis, A., Senapedis, W. T., & Henske, E. P. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi444 · Cited by 85
Polo-like kinase 1 as target for cancer therapy
Weiß, L., & Efferth, T. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-38 · Cited by 84
Polo-like kinase (PLK) expression in endometrial carcinoma
Takai, N., Miyazaki, T., Fujisawa, K., Nasu, K., Hamanaka, R., & Miyakawa, I. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00522-5 · Cited by 82
Harris, P. S., Venkataraman, S., Alimova, I. N., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-80 · Cited by 82
Hikichi, Y., Honda, K., Hikami, K., Miyashita, H., Kaieda, I., Murai, S., Uchiyama, N., Hasegawa, M., Kawamoto, T., Sato, T., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0762 · Cited by 81
Epigenetic Roles of MLL Oncoproteins Are Dependent on NF-κB
Kuo, H.-P., Wang, Z., Lee, D., 岩崎, 正., Duque‐Afonso, J., Wong, S. H. K., Lin, C.-H., Figueroa, M. E., Su, J., Lemischka, I. R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.019 · Cited by 80
Lee, C., Fotovati, A., Triscott, J., Chen, J. Y., Venugopal, C., Singhal, A., Dunham, C. P., Kerr, J. M., Verreault, M., Yip, S. S. F., et al. (2012) · Stem Cells · doi:10.1002/stem.1081 · Cited by 78
Increased Human Polo-Like Kinase-1 Expression in Gliomas
Dietzmann, K., Kirches, E., von Bossanyi, P., Jachau, K., & Mawrin, C. (2001) · Journal of Neuro-Oncology · doi:10.1023/a:1011808200978 · Cited by 76
Bowles, D. W., Diamond, J. R., Lam, E. T., Weekes, C. D., Astling, D. P., Anderson, R. T., Leong, S., Gore, L., Varella‐Garcia, M., Vogler, B. W., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2506 · Cited by 75
Polo-like Kinase 1 Is Involved in Invasion through Extracellular Matrix
Rizki, A., Mott, J. D., & Bissell, M. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2348 · Cited by 75
Overexpression of polo-like kinase1 predicts a poor prognosis in hepatocellular carcinoma patients
He, Z., He, Z., Lin, H., Miao, X., & Zhong, D. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.4177 · Cited by 75
Lin, H.-R., Ting, N. S. Y., Qin, J., & Lee, W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210659200 · Cited by 72
HSF1 as a Mitotic Regulator: Phosphorylation of HSF1 by Plk1 Is Essential for Mitotic Progression
Lee, Y., Kim, E., Lee, J. S., Jeoung, D., Bae, S., Kwon, S., & Lee, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0129 · Cited by 71
Optimized Plk1 PBD Inhibitors Based on Poloxin Induce Mitotic Arrest and Apoptosis in Tumor Cells
Scharow, A., Raab, M., Saxena, K., Sreeramulu, S., Kudlinzki, D., Gande, S. L., Dötsch, C., Kurunci‐Csacsko, E., Klaeger, S., Küster, B., et al. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00565 · Cited by 71
Polo-Like Kinase 1 as Predictive Marker and Therapeutic Target for Radiotherapy in Rectal Cancer
Rödel, F., Keppner, S., Capalbo, G., Bashary, R., Kaufmann, M., Rödel, C. M., Strebhardt, K., & Spänkuch, B. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.100040 · Cited by 70
Danovi, D., Folarin, A., Gogolok, S., Ender, C., Elbatsh, A. M. O., Engström, P. G., Stricker, S. H., Gagrica, S., Georgian, A. R., Yu, D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077053 · Cited by 68
Rudolph, D., Impagnatiello, M. A., Blaukopf, C., Sommer, C., Gerlich, D. W., Roth, M., Tontsch-Grunt, U., Wernitznig, A., Savarese, F., Hofmann, M. H., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.221150 · Cited by 64
Mitotic DNA damage response: Polo-like Kinase-1 is dephosphorylated through ATM-Chk1 pathway
Lee, H. J., Hwang, H.-I., & Jang, Y. (2010) · Cell Cycle · doi:10.4161/cc.9.12.11904 · Cited by 64
Bu, Y., Yang, Z., Li, Q., & Song, F. (2008) · Oncology · doi:10.1159/000151367 · Cited by 62
McCarroll, J. A., Dwarte, T. M., Baigude, H., Dang, J. W., Yang, L., Erlich, R. B., Kimpton, K., Teo, J., Sagnella, S. M., Åkerfeldt, M. C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2664 · Cited by 59
Haupenthal, J., Bihrer, V., Korkusuz, H., Kollmar, O., Schmithals, C., Kriener, S., Engels, K., Pleli, T., Benz, A., Cañamero, M., et al. (2012) · Neoplasia · doi:10.1596/neo.111366 · Cited by 58
Gorlick, R. G., Kolb, E. A., Keir, S. T., Maris, J. M., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R. B., Billups, C. A., Kurmasheva, R. T., et al. (2013) · Pediatric Blood & Cancer · doi:10.1002/pbc.24616 · Cited by 57
ATR Enforces the Topoisomerase II-dependent G2 Checkpoint through Inhibition of Plk1 Kinase
Deming, P. B., Flores, K. G., Downes, C. S., Paules, R. S., & Kaufmann, W. K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206109200 · Cited by 56
Liao, C., Park, J., Bang, J. K., Nicklaus, M. C., & Lee, K. S. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100020e · Cited by 55
Ramani, P., Nash, R. L., Sowa‐Avugrah, E., & Rogers, C. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1900-4 · Cited by 55
Ferrarotto, R., Goonatilake, R., Yoo, S. Y., Tong, P., Giri, U. P., Peng, S., Minna, J. D., Girard, L., Wang, Y., Wang, L., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2890 · Cited by 54
Jimeno, A., Rubio‐Viqueira, B., Rajeshkumar, N. V., Chan, A., Solomon, A., & Hidalgo, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0693 · Cited by 53
Chou, Y.-S., Yen, C., Chen, W., Lin, Y., Wen, Y.-S., Ke, W.-T., Wang, J., Liu, C., Yang, M., Chen, T.-H., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3352 · Cited by 52
Sun, W., Su, Q., Cao, X., Shang, B., Chen, A., Yin, H., & Liu, B. (2014) · International Journal of Genomics · doi:10.1155/2014/312130 · Cited by 50
Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)
Nie, Z., Feher, V. A., Natala, S. R., McBride, C. M., Kiryanov, A. A., Jones, B., Lam, B., Liu, Y., Kaldor, S. W., Stafford, J. A., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.02.083 · Cited by 50
Tut, T. G., Lim, S. H.-S., Dissanayake, I. U., Descallar, J., Chua, W., Ng, W. L., SOUZA, P. D., Shin, J.-S., & Lee, C. S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0129313 · Cited by 47
Izumi, H., Matsumoto, Y., Ikeuchi, T., Saya, H., Kajii, T., & Matsuura, S. (2009) · Oncogene · doi:10.1038/onc.2009.141 · Cited by 47
The FOXM1-PLK1 axis is commonly upregulated in oesophageal adenocarcinoma
Dibb, M. J., Han, N., Choudhury, J., Hayes, S. J., Valentine, H. R., West, C., Ang, Y. S., & Sharrocks, A. D. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.424 · Cited by 45
Polo-like kinase 1 mediates BRCA1 phosphorylation and recruitment at DNA double-strand breaks
Chabalier-Taste, C., Brichese, L., Racca, C., Canitrot, Y., Calsou, P., & Larminat, F. (2016) · Oncotarget · doi:10.18632/oncotarget.6825 · Cited by 44
Zhang, R., Shi, H., Ren, F., Liu, H., Zhang, M., Deng, Y., & Li, X. (2015) · Oncology Reports · doi:10.3892/or.2015.3723 · Cited by 42
Wang, R., Song, Y., Xu, X., Wu, Q., & Liu, C. (2013) · Clinical & Translational Oncology · doi:10.1007/s12094-012-0978-9 · Cited by 42
FOXM1 participates in PLK1-regulated cell cycle progression in renal cell cancer cells
Zhang, Z., Zhang, G., & Kong, C. (2016) · Oncology Letters · doi:10.3892/ol.2016.4228 · Cited by 42
Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma
Cheng, M.-W., Bing-chan, W., Weng, Z.-Q., & Zhu, X.-W. (2011) · Acta Histochemica · doi:10.1016/j.acthis.2011.09.004 · Cited by 41
Polo‐like kinase‐1 phosphorylates MDM2 at Ser260 and stimulates MDM2‐mediated p53 turnover
Dias, S. S., Hogan, C., Ochocka, A. M., & Meek, D. W. (2009) · FEBS Letters · doi:10.1016/j.febslet.2009.09.057 · Cited by 39
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma
Mok, W. C., Wasser, S., Tan, M., & Lim, S. G. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i27.3527 · Cited by 39
Cholewa, B. D., Pellitteri-Hahn, M. C., Scarlett, C. O., & Ahmad, N. (2014) · Journal of Proteome Research · doi:10.1021/pr5002516 · Cited by 39
Ding, Y., Huang, D., Zhang, Z., Smith, J., Petillo, D., Looyenga, B. D., Feenstra, K., MacKeigan, J. P., Furge, K. A., & Teh, B. T. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0076 · Cited by 38
Ligand discovery and virtual screening using the program LIDAEUS
Taylor, P., Blackburn, E. A., Sheng, Y., Harding, S. A., Hsin, K., Kan, D., Shave, S., & Walkinshaw, M. D. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707532 · Cited by 36
Tyagi, S., Bhui, K., Singh, R., Singh, M., Raisuddin, S., & Shukla, Y. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.025 · Cited by 33
Karlin, K. L., Mondal, G., Hartman, J. K., Tyagi, S., Kurley, S. J., Bland, C. S., Hsu, T. Y. T., Renwick, A., Fang, J. E., Migliaccio, I., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.011 · Cited by 33
Identification of novel, potent and selective inhibitors of Polo-like kinase 1
Chen, S., Bartkovitz, D., Cai, J., Chen, Y., Chen, Z., Chu, X., Le, K., Le, N. T., Luk, K., Mischke, S., et al. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.052 · Cited by 32
Donizy, P., Hałoń, A., Surowiak, P., Kaczorowski, M., Kozyra, C., & Matkowski, R. (2016) · Oncology Letters · doi:10.3892/ol.2016.4890 · Cited by 30
BI_2536 - Targeting the Mitotic Kinase Polo-Like Kinase 1 (Plk1)
Wäsch, R., Hasskarl, J., Schnerch, D., & Lübbert, M. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_15 · Cited by 28
BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress
Zou, J., Rezvani, K. S., Wang, H., Lee, K. S., & Zhang, D. (2013) · Cell Cycle · doi:10.4161/cc.25349 · Cited by 28
Strategies to Overcome Resistance to Targeted Protein Kinase Inhibitors in??the Treatment of Cancer
Buschbeck, M. (2006) · Drugs in R&D · doi:10.2165/00126839-200607020-00002 · Cited by 27
PLK1 is a binding partner and a negative regulator of FOXO3 tumor suppressor
Bucur, O., Stancu, A. L., Muraru, M. S., Melet, A., Petrescu, S. M., & Khosravi‐Far, R. (2014) · Discoveries · doi:10.15190/d.2014.8 · Cited by 25
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma
Wei, Chuen, Mok, Shanthi, S. V., Wasser, Theresa, Tan, �., Seng, Gee, & Lim (2012) · World Journal of Gastroenterology · Cited by 18
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
Thrum, S., Lorenz, J., Mössner, J., & Wiedmann, M. W. (2011) · PubMed · Cited by 16
Developments of Polo-like Kinase 1 (Plk1) Inhibitors as Anti-Cancer Agents
Li, S., Zhang, Y., & Xu, W. (2013) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/13895575113136660103 · Cited by 14
Validation of Polo-like kinase 1 as a therapeutic target in pancreatic cancer cells
Zhang, C., Sun, X., Ren, Y., Lou, Y., Zhou, J., Liu, M., & Li, D. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21412 · Cited by 13
Phosphorylation of Tara by Plk1 is essential for faithful chromosome segregation in mitosis
Zhu, Y., Wang, C., Lan, J., Yu, J., Jin, C., & Huang, H. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.07.001 · Cited by 13
Dibb, M. J., Han, N., Choudhury, J., Hayes, S. J., Valentine, H. R., West, C., Sharrocks, A. D., & Ang, Y. S. (2015) · BMC Research Notes · doi:10.1186/s13104-015-1658-y · Cited by 11
Cited by
Mechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Present and Future Perspective on PLK1 Inhibition in Cancer Treatment
Chiappa, M., Petrella, S., Damia, G., Broggini, M., Guffanti, F., & Ricci, F. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.903016 · Cited by 120
Feng, L., Wang, G., Chen, Y., He, G., Liu, B., Liu, J., Chiang, C., & Ouyang, L. (2022) · Medicinal Research Reviews · doi:10.1002/med.21859 · Cited by 65
Cyclers’ kinases in cell division: from molecules to cancer therapy
Milletti, G., Colicchia, V., & Cecconi, F. (2023) · Cell Death & Differentiation · doi:10.1038/s41418-023-01196-z · Cited by 39
Selective Wee1 degradation by PROTAC degraders recruiting VHL and CRBN E3 ubiquitin ligases
Aublette, M. C., Harrison, T. A., Thorpe, E. J., & Gadd, M. S. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128636 · Cited by 35
Metadata
- Authors
- Liu, Z., Sun, Q., & Wang, X.
- Venue
- Translational Oncology
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 10
- Issue
- 1
- Pages
- 22-32
- ISSN
- 1936-5233 (ISSN-L)
- OpenAlex
- W2549761003
- Cited by
- 454
- References
- 119
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.